01:59 AM EDT, 10/23/2026 (MT Newswires) -- Santhera Pharmaceuticals (SANN.SW) said its licensing partner filed a marketing application in South Korea for Duchenne muscular dystrophy treatment Agamree, or vamorolone. The specialty pharmaceutical company said Friday that Nxera Pharma submitted the application to South Korea's Ministry of Food and Drug Safety, following orphan drug and fast-track designations for Agamree in June. Nxera is looking to commercially launch Agamree in South Korea in 2028, following expected market authorization in 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.